Table 2.
Outcome | DOACs group (n = 503) | Warfarin group (n = 508) | Adjusted HR (95% CI)b |
|||||
---|---|---|---|---|---|---|---|---|
Events | PY | Rate (95%CI)a | Events | PY | Rate (95%CI)a | |||
Stroke/SE | 5 | 208 | 2.25 (0.91–5.56) | 17 | 259 | 6.54 (4.06–10.53) | 0.29 (0.09–0.97) | |
Major bleeding | 9 | 208 | 4.33 (2.25–8.33) | 7 | 257 | 2.74 (1.31–5.74) | 0.99 (0.34–2.92) | |
Any ischemia | 17 | 202 | 8.27 (5.12–13.34) | 35 | 248 | 14.18 (10.18–19.74) | 0.42 (0.22–0.79) | |
Any bleeding | 55 | 194 | 28.38 (21.80-36.95) | 65 | 202 | 32.31 (25.33–41.20) | 0.74 (0.50–1.09) |
a Incidence rate, per 100 person-years
b Weighted with inverse probability of treatment weighting (IPTW) and adjusted for age, sex, chronic obstructive pulmonary disease, gastrointestinal ulcer, diuretics, antidiabetics, CHA2DS2-VASc score, HAS-BLED score, smoking status, prior bleeding, cerebrovascular disease, myocardial infarction, peripheral vascular disease, venous thromboembolism, antiplatelets, non-steroidal anti-inflammatory drugs
Abbreviations: DOACs, direct oral anticoagulants; PY person-years; SE systemic embolism